Home › Compare › CZASF vs ABBV
CZASF yields 19801.98% · ABBV yields 3.06%● Live data
📍 CZASF pulled ahead of the other in Year 1
Combined, CZASF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of CZASF + ABBV for your $10,000?
China ZhengTong Auto Services Holdings Limited, an investment holding company, engages in 4S dealership business in the People's Republic of China. The company operates through 4S Dealership Business, Supply Chain Business, Financial Services Business, and Comprehensive Properties Business segments. It is involved in the sale of motor vehicles and automobile parts; and provision of maintenance and repair services. The company also provides motor-related logistics services; and trades in lubricant oil and auto supplies. In addition, it focuses on the dealership of branded automobiles, including Porsche, BMW, Mercedes-Benz, Audi, Jaguar Land Rover, Hongqi, Volvo, Cadillac, and Infiniti; and operates dealership stores of middle market brands, such as Dongfeng-Nissan, Buick, Dongfeng-Honda, FAW-Volkswagen, Chevrolet, FAW Toyota, and Hyundai. Further, the company engages in the development and sale of real estate properties; property management; trading pre-owned automobiles; e-commerce platform; and provision of consulting and automobile trading agency services, as well as insurance agency services. As of December 31, 2021, it operated 118 dealership outlets in 40 cities across 17 provinces and municipalities. The company was founded in 1999 and is headquartered in Beijing, the People's Republic of China.
Full CZASF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.